Overview
Ascend Clinical provides laboratory testing nationwide with a focus on kidney disease and dialysis-related testing, and also conducts environmental water testing including Legionella. It processes patient samples in its own laboratories to generate test results, and offers LabCheck, a web-based SaaS that dialysis clinics use to manage patient care and clinic operations online. The company differentiates itself through its specialized dialysis testing expertise, more than 20 years of experience, a combination of high-volume lab services with a dedicated software platform, and a national footprint. Its goal is to deliver accurate, reliable laboratory services and practical tools to optimize patient care for dialysis clinics and their patients.
Work here?Claim your company
Simplify's take
What believers are saying
- Eurofins closed Ascend's acquisition, expanding U.S. renal and transplant testing immediately.
- Ascend's 24-hour turnaround and overnight shipping support dialysis providers demanding faster clinical decisions.
- Stanford and Siemens partnerships plus AI-enabled renal software strengthen product credibility and stickiness.
What critics are saying
- Quigley v. Eurofins Ascend Clinical, filed August 6, 2026, exposes employment-liability and morale risk.
- Eurofins integration can disrupt customer service, LabCheck workflows, and retention during 2026.
- A CMS dialysis reimbursement change would crush volumes and threaten Ascend's standalone economics.
What makes Ascend Clinical unique
- Ascend serves 80% of independent U.S. dialysis clinics with up to one million daily tests.
- Its LabCheck platform automates ordering, reporting, and critical-result alerts across dialysis workflows.
- Eurofins bought Ascend in 2026, validating its renal-transplant testing franchise and distribution footprint.
Help us improve and share your feedback! Did you find this helpful?